Physician profile
Michelle E Park
NPI 1740694918
$13,133.77
in general payments reported to CMS, 2019-2025
39 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,931 · 2020: $1,499 · 2021: $2,146 · 2022: $1,665 · 2023: $1,045 · 2024: $1,497 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,764 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,764.20 |
| Education | $128.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,610.84 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,406.63 | 2019-2025 | Twyneo, Aklief, Epsolay |
| Regeneron Healthcare Solutions, INC. | $1,199.26 | 2019-2025 | Dupixent |
| Allergan, INC. | $956.53 | 2019-2022 | |
| Janssen Biotech, INC. | $834.19 | 2019-2025 | Tremfya |
| Pfizer INC. | $778.95 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $676.47 | 2019-2025 | Absorica Ld, Winlevi |
| Genzyme Corporation | $627.88 | 2020-2025 | |
| Incyte Corporation | $510.58 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $480.92 | 2019-2025 | |
| Leo Pharma INC. | $366.73 | 2022-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $362.67 | 2019-2022 | |
| Epi Health, LLC | $301.81 | 2019-2022 | |
| Almirall LLC | $288.58 | 2019-2023 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $280.05 | 2019-2025 | Jublia, Cabtreo, Arazlo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $205.29 | 2019-2022 | |
| Amgen INC. | $198.31 | 2019-2025 | Otezla, Otezla |
| Kerecis Limited | $139.93 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Medimetriks Pharmaceuticals, INC. | $94.83 | 2019 | |
| Vyne Pharmaceuticals INC. | $91.08 | 2020-2021 | |
| Merz North America, INC. | $89.93 | 2020-2022 | |
| Dermira, INC. | $78.68 | 2019-2020 | |
| Celgene Corporation | $67.29 | 2019 | |
| Aclaris Therapeutics, INC. | $65.22 | 2019 | |
| Dermavant Sciences, INC. | $58.48 | 2023-2024 | Vtama |
| Coopersurgical, INC. | $54.63 | 2025 | Ally II Ups |
| Ucb, INC. | $54.49 | 2022-2025 | Bimzelx, Cimzia |
| Sanofi Pasteur INC. | $27.39 | 2024 | |
| Botanix Sb INC | $26.93 | 2025 | Sofdra |
| Journey Medical Corporation | $25.96 | 2025 | |
| Dusa Pharmaceuticals, INC. | $24.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.87 | 2020 | |
| Verrica Pharmaceuticals INC. | $21.95 | 2023 | Ycanth |
| Organon LLC | $20.68 | 2025 | Vtama |
| Mylan Pharmaceuticals INC. | $20.01 | 2019 | |
| Lnhc, INC | $19.06 | 2025 | Zelsuvmi |
| Acelrx Pharmaceuticals, INC. | $15.46 | 2022 | |
| Mission Pharmacal Company | $14.56 | 2019 | |
| Promius Pharma LLC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.